WO1995024199A3 - Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer - Google Patents

Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer Download PDF

Info

Publication number
WO1995024199A3
WO1995024199A3 PCT/US1995/003081 US9503081W WO9524199A3 WO 1995024199 A3 WO1995024199 A3 WO 1995024199A3 US 9503081 W US9503081 W US 9503081W WO 9524199 A3 WO9524199 A3 WO 9524199A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
medicament
inhibit
compounds
manufacture
Prior art date
Application number
PCT/US1995/003081
Other languages
French (fr)
Other versions
WO1995024199A2 (en
Inventor
Stuart L Bursten
Glenn C Rice
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Priority to CA002166324A priority Critical patent/CA2166324A1/en
Priority to AU19901/95A priority patent/AU1990195A/en
Priority to EP95912888A priority patent/EP0708645A1/en
Publication of WO1995024199A2 publication Critical patent/WO1995024199A2/en
Publication of WO1995024199A3 publication Critical patent/WO1995024199A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention was made as a result of discovering an entire new approach and therapeutic target of cancer therapy. In addition, a prototype inhibitor compound, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, has been discovered that acts by inhibiting cellular accumulation of specific PA species and is an inhibitor of PC directed PLDβ. Accordingly, the present invention provides a method for treating and preventing the spread of cancers comprising treating a patient with a tumor with an effective amount of a compound that reduces cellular accumulation of PA4 species.
PCT/US1995/003081 1994-03-08 1995-03-08 Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer WO1995024199A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002166324A CA2166324A1 (en) 1994-03-08 1995-03-08 Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer
AU19901/95A AU1990195A (en) 1994-03-08 1995-03-08 Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer
EP95912888A EP0708645A1 (en) 1994-03-08 1995-03-08 Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20876594A 1994-03-08 1994-03-08
US08/208,765 1994-03-08

Publications (2)

Publication Number Publication Date
WO1995024199A2 WO1995024199A2 (en) 1995-09-14
WO1995024199A3 true WO1995024199A3 (en) 1995-11-23

Family

ID=22775965

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/003081 WO1995024199A2 (en) 1994-03-08 1995-03-08 Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer

Country Status (4)

Country Link
EP (1) EP0708645A1 (en)
AU (1) AU1990195A (en)
CA (1) CA2166324A1 (en)
WO (1) WO1995024199A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021344A2 (en) * 1991-05-24 1992-12-10 Fred Hutchinson Cancer Research Center Modulation of cellular response to external stimuli
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
WO1994022863A1 (en) * 1993-03-31 1994-10-13 Cell Therapeutics, Inc. Second messenger cell signaling inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021344A2 (en) * 1991-05-24 1992-12-10 Fred Hutchinson Cancer Research Center Modulation of cellular response to external stimuli
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
WO1994022863A1 (en) * 1993-03-31 1994-10-13 Cell Therapeutics, Inc. Second messenger cell signaling inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancerlit Abstract No. 95604126 & Proc. An nu. Meet.Am.Assoc. Cancer Res., vol. 35, A2441, March 1994 *
Proc. Annu. Meet. Am.Assoc. Cancer Res., v ol. 35, Abstract no. A401, March 1994 *
STUART BURSTEN ET AL.: "Potential role for phosphatidic acid in mediating inflammatory responses to TNF-alpha and IL-1beta", CIRCULATORY SHOCK, vol. 44, no. 1, pages 14 - 29 *

Also Published As

Publication number Publication date
EP0708645A1 (en) 1996-05-01
CA2166324A1 (en) 1995-09-14
AU1990195A (en) 1995-09-25
WO1995024199A2 (en) 1995-09-14

Similar Documents

Publication Publication Date Title
AP1599A (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties.
DE60026538D1 (en) PHARMACEUTICAL PREPARATIONS THE CLAVULANIC ACID OR DERIVATIVES CONTAIN FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
EP1304110A3 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
WO2001027119A3 (en) Substance library containing bicyclic imidazo-5-yl-amines and/or bicyclic imidazo-3-yl-amines
CA2227205A1 (en) Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
NO20066054L (en) treatment with cisplatin and an EGFR inhibitor
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
TW200603804A (en) Treatment with irinotecan (cpt-11) and an EGFR-inhibitor
WO2000076487A3 (en) Use of paclitaxel and steriod derivatives as aromatase inhibitors for the treatment of cancer
MX9707022A (en) Trisubstituted phenyl derivatives.
NZ504928A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
YU69903A (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
GR3029490T3 (en) Use of leflunomid for the inhibition of tumor necrosis factor alpha.
WO1998030585A3 (en) Use of pea3 in tumor suppression
MX2007006927A (en) Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy.
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
GB9907571D0 (en) Compounds
WO1995024199A3 (en) Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer
WO2000006136A3 (en) Therapeutic combination of polyamine with an anticancer agent
WO2001041747A3 (en) Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1995912888

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2166324

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1995912888

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995912888

Country of ref document: EP